Haleon plc Form 6-K Summary
Business Context and Reporting Period
Haleon plc filed a Form 6-K for July 2022, dated July 21, 2022. The filing contains a director and person discharging managerial responsibility (“PDMR”) shareholding notification related to Haleon’s demerger from GSK. It is not a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
No comparable-period financial information is presented. The material event disclosed is the receipt of Haleon ordinary shares by certain PDMRs under the GSK Share Reward Plan in connection with the demerger.
| PDMR | Position | Shares received | Transaction date | Price |
|---|---|---|---|---|
| Tobias Hestler | Chief Financial Officer | 1,033 | July 18, 2022 | Not applicable |
| Amy Landucci | Chief Digital and Technology Officer | 379 | July 18, 2022 | Not applicable |
| Bart Derde | Chief Supply Chain Officer | 837 | July 18, 2022 | Not applicable |
| Jooyong Lee | Head of Strategy and Office of the CEO | 386 | July 18, 2022 | Not applicable |
| Tamara Rogers | Chief Marketing Officer | 937 | July 18, 2022 | Not applicable |
The disclosed transactions totaled 3,572 ordinary shares. The shares were received on the London Stock Exchange under the terms of the demerger and were not purchased at a stated price.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no management guidance, outlook, or risk commentary.
- The shares are described as Haleon ordinary shares of £1.25 each, subject to reduction to 1 pence following the company’s capital reduction; the filing refers investors to the June 1, 2022 prospectus for details.
- The transactions represent share-plan and demerger-related distributions rather than open-market purchases, and therefore do not indicate a purchase price or valuation.
Important Facts for Investors to Verify
- Review the June 1, 2022 prospectus for the demerger terms and capital reduction mechanics.
- Confirm the share-plan treatment, tax implications, and any vesting or disposal restrictions applicable to the received shares.
- Do not use this filing as a source for Haleon’s financial performance, liquidity, leverage, or operating outlook.
- Verify subsequent PDMR notifications for any later sales, transfers, or additional share awards.